Free Trial

enGene (ENGN) Stock Price, News & Analysis

enGene logo
$5.83 -0.13 (-2.18%)
(As of 12/20/2024 05:16 PM ET)

About enGene Stock (NASDAQ:ENGN)

Key Stats

Today's Range
$5.60
$6.54
50-Day Range
$5.83
$9.83
52-Week Range
$4.42
$18.40
Volume
99,164 shs
Average Volume
118,058 shs
Market Capitalization
$257.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.38
Consensus Rating
Buy

Company Overview

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

enGene Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
60th Percentile Overall Score

ENGN MarketRank™: 

enGene scored higher than 60% of companies evaluated by MarketBeat, and ranked 411th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    enGene has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    enGene has only been the subject of 4 research reports in the past 90 days.

  • Read more about enGene's stock forecast and price target.
  • Earnings Growth

    Earnings for enGene are expected to decrease in the coming year, from ($1.52) to ($1.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of enGene is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of enGene is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    enGene has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.14% of the float of enGene has been sold short.
  • Short Interest Ratio / Days to Cover

    enGene has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in enGene has recently decreased by 0.14%, indicating that investor sentiment is improving.
  • Percentage of Shares Shorted

    4.14% of the float of enGene has been sold short.
  • Short Interest Ratio / Days to Cover

    enGene has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in enGene has recently decreased by 0.14%, indicating that investor sentiment is improving.
  • News Sentiment

    enGene has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for enGene this week, compared to 22 articles on an average week.
  • Search Interest

    Only 7 people have searched for ENGN on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, enGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,651,103.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about enGene's insider trading history.
Receive ENGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter.

ENGN Stock News Headlines

Positive Developments in enGene Holdings’ LEGEND Trial Support Buy Rating
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
enGene to Participate in Upcoming Investor Conferences
enGene to Participate in Upcoming Investor Conferences
See More Headlines

ENGN Stock Analysis - Frequently Asked Questions

enGene's stock was trading at $9.23 at the start of the year. Since then, ENGN shares have decreased by 36.8% and is now trading at $5.83.
View the best growth stocks for 2024 here
.

enGene Holdings Inc. (NASDAQ:ENGN) announced its quarterly earnings data on Thursday, December, 19th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06.

enGene's top institutional investors include Franklin Resources Inc. (2.69%), Point72 Asset Management L.P. (1.50%) and Wolverine Asset Management LLC (0.01%). Insiders that own company stock include De Solidarite Des Travai Fonds and Growth Opportunities F Forbion.
View institutional ownership trends
.

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
12/19/2024
Today
12/22/2024
Fiscal Year End
10/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ENGN
Previous Symbol
NASDAQ:ENGN
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.38
High Stock Price Target
$40.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+421.0%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Net Income
$-99,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$3.51 per share
Book Value
$3.12 per share

Miscellaneous

Free Float
38,158,000
Market Cap
$257.78 million
Optionable
N/A
Beta
-0.78
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:ENGN) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners